MCL Literature Feed

A case report of an elderly MCL patient with sequential relapses in rare extranodal sites (ocular adnexa, soft tissue, heart) highlights the need for vigilance for unusual disease presentations.

The novel, chemotherapy-free triplet of alisertib, ibrutinib, and rituximab demonstrates clinical activity in MCL, providing a new therapeutic strategy for likely relapsed/refractory patients.

This case report describes a rare MCL CNS relapse presenting as Horner syndrome and oculomotor nerve palsy, highlighting the need for CSF analysis in patients with atypical neurological symptoms, even with normal imaging.

This systematic review of brexu-cel for relapsed/refractory MCL reveals conflicting cost-effectiveness conclusions across different countries, highlighting major uncertainties for health systems considering its adoption and reimbursement.

This general review contextualizes CAR T-cell therapy, including its approved use in mantle cell lymphoma, within the broader landscape of cellular therapies, summarizing its efficacy and common toxicities.

This review outlines the clinical landscape and practical application of CAR-T and bispecific antibodies for relapsed/refractory MCL, guiding their integration into practice after targeted therapy failure.

This review synthesizes the evolution of BTK-targeted therapies, from covalent inhibitors to non-covalent agents and degraders, outlining current treatment paradigms and future combination strategies for frontline and relapsed MCL.

Reviewing AIM and SYMPATICO trials, the ibrutinib-venetoclax combination shows high efficacy in relapsed/refractory MCL, supporting a potential fixed-duration, MRD-guided treatment strategy.

This review summarizes the clinical development and efficacy of BTK inhibitors in MCL, detailing common resistance mutations and outlining future directions for this crucial targeted therapy class.

The first approval of odronextamab, a CD20xCD3 bispecific antibody, in other lymphomas introduces a promising off-the-shelf, T-cell engaging immunotherapy for potential use in relapsed/refractory MCL.

This review summarizes the established efficacy and toxicities of CD19 CAR-T therapy in B-cell lymphomas, including MCL, while highlighting future research directions like novel targets and sequencing with bispecifics.

This phase 1 trial establishes the safety and preliminary efficacy of combining the HDAC inhibitor abexinostat with ibrutinib in relapsed/refractory MCL, suggesting a potential new BTKi-based combination strategy.

The polatuzumab-based regimen, Pola-R-mini-CHP, demonstrated efficacy in elderly relapsed/refractory MCL, offering a potential new ADC-chemoimmunotherapy option for this difficult-to-treat population.

Real-world, intention-to-treat data from the French DESCAR-T registry confirms brexucabtagene autoleucel efficacy in relapsed/refractory MCL, providing practical outcomes for all patients intended for treatment.

This meta-analysis quantifies the poor prognosis (median OS ~9 months) for r/r MCL patients post-covalent BTKi treated with standard therapies, highlighting the superior efficacy of brexucabtagene autoleucel.

MCL can relapse late as isolated soft tissue tumors in the extremities, a rare clinical presentation clinicians must recognize for timely diagnosis, even without concurrent nodal disease.

The VALERIA trial demonstrates that an MRD-guided, fixed-duration venetoclax-lenalidomide-rituximab regimen is a highly effective, personalized, chemotherapy-free strategy for patients with relapsed/refractory MCL.

Longitudinal single-cell analysis of refractory MCL reveals co-evolving tumor heterogeneity and immune evasion, providing a roadmap for overcoming treatment resistance and identifying new therapeutic targets.

This review positions pirtobrutinib, a non-covalent BTKi, as a highly effective and safe treatment for relapsed/refractory MCL, especially for patients who have progressed on prior covalent BTK inhibitors.

The KRD regimen (carfilzomib, lenalidomide, dexamethasone) is highly toxic and ineffective for BTKi-relapsed/refractory MCL, with only 13% 12-month OS, establishing this is not a viable salvage therapy.

Real-world US Medicare data shows elderly MCL patients post-cBTKi have a dismal median OS of 9.4 months and high costs, highlighting the urgent need for effective therapies.

The non-covalent BTK inhibitor pirtobrutinib shows a 58% overall response rate in relapsed/refractory MCL, providing a crucial new option for patients previously treated with covalent BTK inhibitors.

Bioinformatic analysis of public datasets identified key genes and pathways driving bortezomib resistance in MCL, providing potential biomarkers and therapeutic targets for the relapsed/refractory setting.

This review synthesizes current data and practical considerations for CAR-T and bispecific antibodies, guiding clinical decision-making and sequencing for these T-cell engaging therapies in relapsed/refractory MCL.

This review explores CAR-NK cells as a promising alternative to CAR-T therapy for mantle cell lymphoma, potentially offering comparable efficacy with a significantly improved safety profile and fewer severe toxicities.

This CML review details targeting the ubiquitin-proteasome system to overcome TKI resistance, offering a potential mechanistic strategy for addressing BTKi resistance in MCL.

A meta-analysis of 7,604 patients found mantle cell lymphoma has the highest non-relapse mortality (10.6%) post-CAR-T, with infections being the primary cause, not CAR-T-specific toxicities.

The non-covalent BTK inhibitor pirtobrutinib is now approved in Japan for mantle cell lymphoma, providing a crucial new therapeutic option for patients, including those resistant to covalent BTKis.

This review synthesizes current and emerging therapies for relapsed/refractory MCL, including BTKi, BCL2i, CAR-T, and bispecifics, emphasizing the evolving challenge of post-BTKi treatment sequencing.

In younger, BTKi-naïve MCL patients with late relapse (>24 months), second-line BTKi significantly improved PFS and OS versus chemoimmunotherapy, establishing it as the preferred approach in this setting.